Related Experiment Video
Updated: Aug 9, 2026
Culture of myeloid dendritic cells from bone marrow precursors
Published on: July 26, 2008
Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities
M Mohty1, D Jarrossay, M Lafage-Pochitaloff
1Laboratoire d'Immunologie des Tumeurs, Université de la Méditerranée, Marseille, France.
Insights
Dendritic cells (DCs), crucial for immune responses, show significant quantitative imbalances in acute myeloid leukemia (AML) patients. This imbalance in myeloid DCs (MDCs) and plasmacytoid DCs (PDCs) may impair immune control during leukemia.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Dendritic cells (DCs) initiate immune responses and T cell polarization.
- Two main blood DC subsets exist: myeloid DCs (MDCs) and plasmacytoid DCs (PDCs).
Purpose of the Study:
- To investigate the quantitative profiles of MDC and PDC subsets in patients with acute myeloid leukemia (AML).
- To assess the functional capacity of leukemic DC subsets ex vivo.
Main Methods:
- Flow cytometry was used to quantify MDC and PDC subsets in 37 AML patients.
- Ex vivo functional assays evaluated maturation, allostimulatory activity, and interferon-alpha secretion of leukemic DCs.
Main Results:
- Significant quantitative imbalances in MDC and PDC subsets were observed in 59% of AML patients.
- Leukemic PDCs, unlike MDCs, exhibited impaired maturation and reduced allostimulatory capacity.
- Leukemic PDCs showed altered interferon-alpha secretion.
Conclusions:
- Leukemic processes quantitatively alter circulating dendritic cell subsets in vivo.
- Dysfunctional leukemic PDCs may contribute to immune evasion in acute myeloid leukemia.
- These findings highlight the role of dendritic cells in leukemia pathogenesis and immune escape.
Abstract:
Dendritic cells (DCs) are responsible for the initiation of immune responses. Two distinct subsets of blood DCs have been characterized thus far. Myeloid DCs (MDCs) and plasmacytoid monocytes (PDCs) were shown to be able to promote polarization of naive T cells. This study shows a dramatic quantitative imbalance in both circulating blood DC subsets in 37 patients with acute myeloid leukemias. Eleven patients (30%) displayed a normal quantitative profile (MDC mean, 0.37% +/- 0.21%; range, 0.01% to 0.78%; PDC mean, 0.21% +/- 0.24%; range, 0.04% to 0.62%), whereas 22 (59%) showed a tremendous expansion of MDCs (9 patients: mean, 16.76% +/- 14.03%; range, 1.36% to 41%), PDCs (4 patients: mean, 7.28% +/- 6.84%; range, 1% to 14%), or both subsets (9 patients: MDC mean, 10.86% +/- 12.36%; range, 1.02% to 37.1%; PDC mean, 4.25% +/- 3.78%; range, 1.14% to 13.04%). Finally, in 4 patients (11%), no DC subsets were detectable. Both MDC and PDC subsets exhibited the original leukemic chromosomal abnormality. Ex vivo, leukemic PDCs, but not leukemic MDCs, had impaired capacity for maturation and decreased allostimulatory activity. Also, leukemic PDCs were altered in their ability to secrete interferon-alpha. These data provide evidence that DC subsets in vivo may be affected by leukemogenesis and may contribute to leukemia escape from immune control.
